Cancer gene study aims to unlock prognosis secrets

NCT ID NCT07622667

Recruiting now Knowledge-focused Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is collecting medical data and tumor or blood samples from 500 adults with malignant tumors treated at a Chinese hospital between 2017 and 2025. Researchers will analyze genes, immune cells, and other molecular features to understand what affects survival and treatment response. The goal is to build better tools for predicting outcomes and personalizing cancer care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors better predict cancer outcomes and identify new targets for treatment.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly benefit participants. Results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT TUMORS

Contacts and locations

Locations

Nanfang Hospital, Southern Medical University
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.